Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 11/20 | 0.40 |
| ▸ | APP | P05067 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | PRKDC | P78527 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1841743 | 0.99 | SIGMAR1 (0.42) | SIGMAR1APPCYP3A4ALDH1A1MEN1 | |
| SCHEMBL416061 | 0.84 | ALDH1A1 (0.36) | CYP3A4ALDH1A1 | |
| SCHEMBL5601645 | 0.84 | ALDH1A1 (0.36) | CYP3A4ALDH1A1 | |
| SCHEMBL1836785 | 0.73 | ALDH1A1 (0.45) | CYP3A4ALDH1A1MEN1SLC6A3KMT2A | |
| SCHEMBL1841634 | 0.72 | ALDH1A1 (0.41) | SIGMAR1CYP3A4ALDH1A1MEN1KMT2A | |
| SCHEMBL1840906 | 0.72 | ALDH1A1 (0.41) | CYP3A4ALDH1A1 | |
| SCHEMBL1838877 | 0.71 | ALDH1A1 (0.40) | CYP3A4ALDH1A1 | |
| SCHEMBL1843106 | 0.71 | ALDH1A1 (0.45) | CYP3A4ALDH1A1MEN1TSHRKMT2A | |
| SCHEMBL1840645 | 0.71 | HPGD (0.41) | CYP3A4ALDH1A1MEN1CYP2D6TSHR | |
| SCHEMBL1840003 | 0.70 | ALDH1A1 (0.43) | CYP3A4ALDH1A1SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7273856-B2 | Linear basic compounds having NK-2 antagonist activity and formulations thereof | MENARINI RICERCHE S.P.A. (IT) | 2007-09-25 | — | — | US | disclosed |
| EP-1442050-B1 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI SAS (IT) | 2006-09-13 | — | — | EP | disclosed |
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | MALESCI INSTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2004-12-23 | — | — | US | disclosed |
| EP-1442050-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.p.A. (IT) | 2004-08-04 | — | — | EP | disclosed |
| WO-2003037916-A2 | LINEAR BASIC COMPOUNDS HAVING NK-2 ANTAGONIST ACTIVITY AND FORMULATIONS THEREOF | MALESCI ISTITUTO FARMACOBIOLOGICO S.P.A. (IT) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040259930-A1 | Linear basic compounds having nk-2 antagonist activity and formulations thereof | BDKRB2, BDKRB1, TACR2 | SIGMAR1 414/4885APP 3200/4885CYP3A4 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.